Premium
A bioluminescent HL‐60 cell line to assay anti‐leukaemia therapeutics under physiological conditions
Author(s) -
Isaza Maria P.,
Chau Jennie T.,
Le Amy,
Balashova Nataliya V.,
Patel Jigna K.,
Salerno Erica,
Crosby Juan A.,
O'Connor Anna,
Kachlany Scott C.
Publication year - 2007
Publication title -
luminescence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 45
eISSN - 1522-7243
pISSN - 1522-7235
DOI - 10.1002/bio.1010
Subject(s) - trypan blue , bioluminescence , cell culture , viability assay , luciferase , in vivo , cell , microbiology and biotechnology , biology , chemistry , cancer research , biochemistry , transfection , genetics
Screens for compounds and proteins with anti‐cancer activity employ viability assays using relevant cancer cell lines. For leukaemia studies, the human leukaemia cell line, HL‐60, is often used as a model system. To facilitate the discovery and investigation of anti‐leukaemia therapeutics under physiological conditions, we have engineered HL‐60 cells that stably express firefly luciferase and produce light that can be detected using an in vivo imaging system (IVIS). Bioluminescent HL‐60 luc cells could be rapidly detected in whole blood with a sensitivity of approximately 1000 viable cells/200 µl blood. Treatment of HL‐60 luc cells with the drug chlorambucil revealed that the bioluminescent viability assay is able to detect cell death earlier than the Trypan blue dye exclusion assay. HL‐60 luc cells administered intraperitoneally (i.p.) or intravenously (i.v.) were visualized in living mice. The rapidity and ease of detecting HL‐60 luc cells in biological fluid indicates that this cell line could be used in high‐throughput screens for the identification of drugs with anti‐leukaemia activity under physiological conditions. Copyright © 2007 John Wiley & Sons, Ltd.